UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A/A
(Amendment No. 2)
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Idera Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
Delaware
|
|
04-3072298 |
|
|
|
(State of Incorporation or Organization)
|
|
(I.R.S. Employer Identification No.) |
|
|
|
167 Sidney Street
Cambridge, Massachusetts
|
|
02139 |
|
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class
to be so registered
Common Stock (and associated Series C Junior
Participating Preferred purchase rights),
$0.001 par value per share
|
|
Name of each exchange on which
each class is to be registered
The NASDAQ Stock Market LLC |
|
|
|
If this form relates to the
registration of a class of securities
pursuant to Section 12(b) of the
Exchange Act and is effective pursuant
to General Instruction A.(c), please
check the following box. þ
|
|
If this form relates to the registration of a class of
securities pursuant to Section 12(g) of the Exchange Act
and is effective pursuant to General Instruction A.(d),
check the following box. o |
Securities Act registration statement file number to which this form relates: N/A (if applicable)
Securities to be registered pursuant to Section 12(g) of the Act: None
TABLE OF CONTENTS
INFORMATION REQUIRED IN REGISTRATION STATEMENT
This Amendment No. 2 on Form 8-A/A amends the Form 8-A (File No. 001-31918) filed by the
registrant with the Securities and Exchange Commission on December 4, 2003. The Company is filing
this amendment in connection with the transfer of the listing of its Common Stock from the American
Stock Exchange to the NASDAQ Stock Market LLC, which is expected to become effective on December
10, 2007.
Item 1. Description of Registrants Securities to be Registered.
The description of the common stock, par value $0.001 per share and preferred stock, par value
$.01 per share of Idera Pharmaceuticals, Inc. (the Registrant) contained in its Registration
Statement on Form 8-A (File No. 001-31918) filed with the Securities and Exchange Commission on
December 4, 2003, pursuant to Section 12 of the Exchange Act, including any subsequently filed
amendments and reports updating such description, is incorporated by reference into this
registration statement.
Item 2. Exhibits.
In accordance with the Instructions as to Exhibits section of Form 8-A, no exhibits are
required to be filed because no other securities of the Registrant are registered on The Nasdaq
Stock Market LLC, and the securities registered hereby are not to be registered pursuant to Section
12(g) of the Securities Exchange Act of 1934.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the
registrant has duly caused this Amendment No. 2 to the Registration Statement on Form 8-A to be
signed on its behalf by the undersigned, thereto duly authorized.
|
|
|
|
|
|
IDERA PHARMACEUTICALS, INC.
|
|
Date: December 7, 2007 |
By: |
/s/ Sudhir Agrawal
|
|
|
|
Sudhir Agrawal, D. Phil. |
|
|
|
Chief Executive Officer and
Chief Scientific Officer |
|
|